Open Access
Med Sci (Paris)
Volume 37, Number 12, Décembre 2021
Vésicules extracellulaires
Page(s) 1178 - 1179
Section Le Magazine
Published online 20 December 2021
  1. rgp120 HIV Vaccine Study Group. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005; 191 : 654–65. [CrossRef] [PubMed] [Google Scholar]
  2. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomized, placebo-controlled, test-of-concept trial. Lancet 2008 ; 372 : 1881–1893. [CrossRef] [PubMed] [Google Scholar]
  3. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009 ; 361 : 2209–2220. [CrossRef] [PubMed] [Google Scholar]
  4. Hammer SM, Sobieszczyk ME, Holly J, et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med 2013 ; 369 : 2083–2092. [CrossRef] [PubMed] [Google Scholar]
  5. Gray GE, Bekker LG, Laher F, et al. Vaccine efficacy of ALVAC-HIV and bivalent subtype C gp120-MF59 in adults. N Engl J Med 2021; 384 : 1089–100. [CrossRef] [PubMed] [Google Scholar]
  6. Burton DR, Desrosiers RC, Doms RW, et al. A sound rationale needed for phase III HIV-1 vaccine trials. Science 2004 ; 303 : 316. [CrossRef] [PubMed] [Google Scholar]
  7. Sok D, Burton DR. Recent progress in broadly neutralizing antibodies to HIV. Nat Immunol 2018 ; 19 : 1179–1188. [CrossRef] [PubMed] [Google Scholar]
  8. Barin F, Stefic K. Anticorps neutralisants tri-specifiques : une solution pour l’immunoprophylaxie ou l’immunothérapie anti-VIH. Med Sci (Paris) 2018 ; 34 : 109–111. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  9. Pegu A, Hessell AJ, Mascola JR, Haigwood NL. Use of broadly neutralizing antibodies for HIV-1 prevention. Immunol Rev 2017 ; 275 : 296–312. [CrossRef] [PubMed] [Google Scholar]
  10. Barin F, Braibant M. HIV-1 antibodies in prevention of transmission. Curr Opin HIV AIDS 2019 ; 14 : 273–278. [CrossRef] [PubMed] [Google Scholar]
  11. Wu X, Yang ZY, Li Y, et al. Rational design of envelopes identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010 ; 329 : 856–861. [CrossRef] [PubMed] [Google Scholar]
  12. Corey L, Gilbert PB, Juraska M, et al. Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition. N Engl J Med 2021; 384 : 1003–14. [CrossRef] [PubMed] [Google Scholar]
  13. Rodger AJ, Cambiano V, Bruun T, et al. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. Lancet 2019 ; 393 : 2428–2438. [CrossRef] [PubMed] [Google Scholar]
  14. Walker B. The AMP trials: a glass half full. N Engl J Med 2021; 384 : 1068–9. [CrossRef] [PubMed] [Google Scholar]
  15. Kwong PD, Mascola JR. HIV-1 vaccines based on antibody identification, B cell ontogeny, and epitope structure. Immunity 2018 ; 48 : 855–871. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.